ScreenerHero

GYRE Gyre Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · gyretx.com
7.040USD-0.56%Mkt Cap: 746.48M $P/E: —

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfe…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap746.48M USD
Enterprise Value736.33M USD
Revenue (TTM)109.82M USD
Gross Profit111.17M USD
Net Income (TTM)5.03M USD
Revenue/Share1.17 USD
Last Price7.040 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees625
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)118.00
PEG—
EV/EBITDA-60.70
EV/Revenue6.71
P/S6.84
P/B6.95
EPS (TTM)-0.25
EPS (Forward)0.06
52W Range
5.46040% of range9.420
52W High9.420 USD
52W Low5.460 USD
Profitability
Gross Margin95.35%
Oper. Margin-47.62%
EBITDA Margin-11.05%
Profit Margin4.31%
ROE4.74%
ROA3.03%
Growth
Revenue Growth-2.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF1.01M USD
CapEx (TTM)1.92M USD
FCF Margin1.71%
FCF Yield0.25%
Net Debt-71.38M USD
Net Debt/EBITDA5.88
Balance Sheet
Debt/Equity0.01
Current Ratio4.26
Quick Ratio3.59
Book Value/Sh1.02 USD
Cash/Share0.70 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 12, 2023
Splits
Last Split1:15
Split DateOct 31, 2023
Analyst Consensus
Rating—
Target (Mean)18.67 USD
Upside (mean)+165.2%
Target Range18.00 USD – 20.00 USD
18.00+165.2% to mean20.00
# Analysts3
Ownership
Shares Out.106.03M
Float35.94M
Insiders74.40%
Institutions8.24%
Short Interest
Short Ratio24.8d
Short % Float5.82%
Short % Out.1.63%
Shares Short1.73M
Short (prev mo.)1.75M
Technical
SMA 506.774 (+3.9%)
SMA 2007.077 (-0.5%)
Beta4.74
S&P 52W Chg16.45%
Avg Vol (30d)156.84K
Avg Vol (10d)165.81K
Technical Indicators
RSI (14)50.1
MACD0.1255
MACD Signal0.1746
MACD Hist.-0.0491
BB Upper7.732 USD
BB Middle7.162 USD
BB Lower6.593 USD
BB Width15.91%
ATR (14)0.3439 USD
Vol Ratio (20d)0.48x